TY - JOUR
T1 - Existing and emerging therapies for managing constipation and diarrhea
AU - Bharucha, Adil E.
AU - Wouters, Mira M.
AU - Tack, Jan
N1 - Funding Information:
Dr. Bharucha serves as a consultant for Allergan Pharmaceuticals. Dr. Wouters has no conflict of interest. Dr. Tack has given Scientific advice to Abide Therapeutics, AlfaWassermann, Allergan, Christian Hansen, Danone, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Novartis, Nutricia, Rhythm, Shionogi, Shire, SK Life Sciences, Takeda, Theravance, Tsumura, Yuhan, Zealand and Zeria pharmaceuticals, has received research grants or support from Abide Therapeutics, Shire, Tsumura, Zeria and has served on the Speaker bureau for Abbott, Allergan, AstraZeneca, Janssen, Kiowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda and Zeria pharmaceuticals.
Funding Information:
This study was supported in part by USPHS NIH Grants R01 DK78924 to AEB, by research grant G.0699.10N from the Fund for Scientific Research ( FWO ) Flanders (Belgium) to MMW.
Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/12
Y1 - 2017/12
N2 - Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.
AB - Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (i.e., constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.
UR - http://www.scopus.com/inward/record.url?scp=85034422540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034422540&partnerID=8YFLogxK
U2 - 10.1016/j.coph.2017.10.015
DO - 10.1016/j.coph.2017.10.015
M3 - Review article
C2 - 29172123
AN - SCOPUS:85034422540
SN - 1471-4892
VL - 37
SP - 158
EP - 166
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
ER -